278 related articles for article (PubMed ID: 28986061)
1. Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score.
Polovina M; Đikić D; Vlajković A; Vilotijević M; Milinković I; Ašanin M; Ostojić M; Coats AJS; Seferović PM
Int J Cardiol; 2017 Dec; 249():191-197. PubMed ID: 28986061
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score.
Pastori D; Farcomeni A; Poli D; Antonucci E; Angelico F; Del Ben M; Cangemi R; Tanzilli G; Lip GY; Pignatelli P; Violi F
Intern Emerg Med; 2016 Mar; 11(2):199-204. PubMed ID: 26471883
[TBL] [Abstract][Full Text] [Related]
3. Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation.
Polovina M; Hindricks G; Maggioni A; Piepoli M; Vardas P; Ašanin M; Ðikic D; Ðuricic N; Milinkovic I; Seferovic PM
Eur Heart J; 2018 Dec; 39(45):4030-4039. PubMed ID: 30101326
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation.
Rivera-Caravaca JM; Marín F; Esteve-Pastor MA; Raña-Míguez P; Anguita M; Muñiz J; Cequier Á; Bertomeu-Martínez V; Valdés M; Vicente V; Lip GYH; Roldán V
Am J Cardiol; 2017 Dec; 120(12):2176-2181. PubMed ID: 29111209
[TBL] [Abstract][Full Text] [Related]
5. Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
Ding WY; Fawzy AM; Romiti GF; Proietti M; Pastori D; Huisman MV; Lip GYH;
J Thromb Thrombolysis; 2024 Jan; 57(1):39-49. PubMed ID: 37566295
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study.
Sanmartín Fernández M; Anguita Sánchez M; Arribas F; Barón-Esquivias G; Barrios V; Cosin-Sales J; Esteve-Pastor MA; Freixa-Pamias R; Lekuona I; Pérez-Cabeza AI; Ureña I; Vázquez Rodríguez JM; Rafols Priu C; Marin F
Cardiol J; 2022; 29(4):601-609. PubMed ID: 35621092
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients.
Pastori D; Rivera-Caravaca JM; Esteve-Pastor MA; Roldán V; Marín F; Pignatelli P; Violi F; Lip GYH
Circ J; 2018 Apr; 82(5):1286-1292. PubMed ID: 29553090
[TBL] [Abstract][Full Text] [Related]
8. Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation.
Rivera-Caravaca JM; Teruel-Montoya R; Roldán V; Cifuentes-Riquelme R; Crespo-Matas JA; de Los Reyes-García AM; Águila S; Fernández-Pérez MP; Reguilón-Gallego L; Zapata-Martínez L; García-Barberá N; Vicente V; Marín F; Martínez C; González-Conejero R
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33198388
[No Abstract] [Full Text] [Related]
9. Effects of Atrial Fibrillation and Chronic Kidney Disease on Major Adverse Cardiovascular Events.
Ding WY; Lip GYH; Pastori D; Shantsila A
Am J Cardiol; 2020 Oct; 132():72-78. PubMed ID: 32773222
[TBL] [Abstract][Full Text] [Related]
10. QTc interval, cardiovascular events and mortality in patients with atrial fibrillation.
Reusser A; Blum S; Aeschbacher S; Eggimann L; Ammann P; Erne P; Moschovitis G; Di Valentino M; Shah D; Schläpfer J; Manser S; Reichlin T; Kühne M; Sticherling C; Osswald S; Conen D
Int J Cardiol; 2018 Feb; 252():101-105. PubMed ID: 29203211
[TBL] [Abstract][Full Text] [Related]
11. Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.
Raparelli V; Pastori D; Pignataro SF; Vestri AR; Pignatelli P; Cangemi R; Proietti M; Davì G; Hiatt WR; Lip GYH; Corazza GR; Perticone F; Violi F; Basili S;
Intern Emerg Med; 2018 Aug; 13(5):651-660. PubMed ID: 29582316
[TBL] [Abstract][Full Text] [Related]
12. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors.
Pastori D; Pignatelli P; Angelico F; Farcomeni A; Del Ben M; Vicario T; Bucci T; Raparelli V; Cangemi R; Tanzilli G; Lip GYH; Violi F
Chest; 2015 Jun; 147(6):1644-1650. PubMed ID: 25429521
[TBL] [Abstract][Full Text] [Related]
13. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.
Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F
Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513
[TBL] [Abstract][Full Text] [Related]
14. Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients.
Perri L; Pastori D; Pignatelli P; Violi F; Loffredo L
Int J Cardiol; 2015 Jan; 179():139-43. PubMed ID: 25464433
[TBL] [Abstract][Full Text] [Related]
15. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study.
Potpara TS; Stankovic GR; Beleslin BD; Polovina MM; Marinkovic JM; Ostojic MC; Lip GYH
Chest; 2012 Feb; 141(2):339-347. PubMed ID: 21622553
[TBL] [Abstract][Full Text] [Related]
16. Relation of Atrial Fibrillation to Angiographic Characteristics and Coronary Artery Disease Severity in Patients Undergoing Percutaneous Coronary Intervention.
Pastori D; Biccirè FG; Lip GYH; Menichelli D; Pignatelli P; Barillà F; Violi F; Gaudio C; Tanzilli G
Am J Cardiol; 2021 Feb; 141():1-6. PubMed ID: 33220321
[TBL] [Abstract][Full Text] [Related]
17. Effect of atrial fibrillation on outcome in patients with known or suspected coronary artery disease referred for exercise stress testing.
Bouzas-Mosquera A; Peteiro J; Broullón FJ; Alvarez-García N; Mosquera VX; Casas S; Pérez A; Méndez E; Castro-Beiras A
Am J Cardiol; 2010 May; 105(9):1207-11. PubMed ID: 20403467
[TBL] [Abstract][Full Text] [Related]
18. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors.
Crandall MA; Horne BD; Day JD; Anderson JL; Muhlestein JB; Crandall BG; Weiss JP; Osborne JS; Lappé DL; Bunch TJ
Pacing Clin Electrophysiol; 2009 Aug; 32(8):981-6. PubMed ID: 19659615
[TBL] [Abstract][Full Text] [Related]
19. Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography.
Gaggin HK; Liu Y; Lyass A; van Kimmenade RR; Motiwala SR; Kelly NP; Mallick A; Gandhi PU; Ibrahim NE; Simon ML; Bhardwaj A; Belcher AM; Harisiades JE; Massaro JM; D'Agostino RB; Januzzi JL
Circulation; 2017 Jan; 135(2):116-127. PubMed ID: 27881568
[TBL] [Abstract][Full Text] [Related]
20. Mitral annular calcification predicts cardiovascular morbidity and mortality in middle-aged patients with atrial fibrillation: the Belgrade Atrial Fibrillation Study.
Potpara TS; Vasiljevic ZM; Vujisic-Tesic BD; Marinkovic JM; Polovina MM; Stepanovic JM; Stankovic GR; Ostojic MC; Lip GYH
Chest; 2011 Oct; 140(4):902-910. PubMed ID: 21436252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
